Sunscreens

Published on 15/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1603 times

Chapter 20 Sunscreens

INTRODUCTION

Increased outdoor leisure time, decreased clothing coverage, a diminishing stratospheric ozone layer, and the rise in popularity of indoor tanning have added up to a significant increase in ultraviolet (UV) radiation exposure in the last century. Skin cancer represents over 50% of all cancers in the US annually; the incidence of melanoma alone has more than tripled in the past two decades. Although UV radiation’s role as a cutaneous carcinogen was reported in the medical literature as early as the 1930s, and in the lay press in the 1940s and 1950s, general public recognition of the danger is a much more recent phenomenon. Additionally, increasing awareness of the causal relationship between UV exposure and the signs of aging, including wrinkling and dyspigmentation, has triggered widespread interest in sun protective products as cosmeceuticals.

In 1978, the US Food and Drug Administration (FDA) reclassified sunscreens from ‘cosmetics’, intended to minimize sunburn and promote tanning, to over-the-counter ‘drugs’, intended to reduce the harmful effects of UV radiation on skin structure and function. However, it was not until May 1999 that the FDA published its monograph addressing the testing and labeling of sunscreen products for the prevention of UVB damage, i.e. sunburn. Although implementation was scheduled for December 2002, the effective date of the sunscreen monograph was delayed pending the development of a proposed amendment to define requirements for broad-spectrum UV coverage including UVA. As of August 2007, the FDA proposed new regulations that address formulation, labeling, and testing requirements for both UVB and UVA radiation protection. At the time of this writing, publication of set rules is pending definitive review of all suggestions and comments from the American Academy of Dermatology and general public.

CHEMICAL SUNSCREENS

The first commercial chemical sunscreen was introduced in 1928; it contained benzyl salicylate and benzyl cinnamate. In 1942, p-aminobenzoic acid (PABA) ointment was shown to be an effective sunburn protectant. This advance led to the development of many new sunscreen agents. In 1999, the FDA monograph included 14 chemical sunscreen agents considered safe and effective for use in over-the-counter (OTC) products.

The FDA-approved chemical sunscreens and the maximum allowed concentration for each are listed in Table 20.1. These ‘sunscreen active ingredients’ are defined as absorbing, reflecting, or scattering radiation in the ultraviolet range at wavelengths of 290–400 nm. The chemical (also called organic or soluble) sunscreen active ingredients prevent sunburn by absorbing UV radiation as photons of light energy that are transformed into harmless long wave radiation and then re-emitted as heat. The FDA defined maximum, rather than minimum, concentrations of each to avoid subjecting consumers to unnecessarily high levels of any active ingredient in sunscreen combination products. This provision also recognizes that final product testing, not the concentration of each active ingredient, determines efficacy.

Table 20.1 Sunscreen active ingredients: chemical

Active ingredient Maximum concentration (%)
Aminobenzoic acid (PABA) 15
Avobenzone 3
Cinoxate 3
Dioxybenzone 3
Ecamsule 10
Homosalate 15
Methyl anthranilate 5
Octocrylene 10
Octyl methoxycinnamate 10
Octyl salicylate 5
Oxybenzone 6
Padimate O 8
Phenylbenzimidazole sulfonic acid 4
Sulisobenzone 10
Trolamine salicylate 12

PHYSICAL SUNSCREENS

Opaque topical agents applied thickly on the skin surface have been used for decades to protect against sunburn. During the Second World War, red veterinary petrolatum was used by the military as a physical sunblock. In the 1950s, it became commonplace to see lifeguards and fair skinned children at the beach with solid white streaks of zinc oxide paste on their noses, lips, and cheeks. These products were messy and not conducive to widespread application. Over the last decade, cosmetic industry technology has been applied to the development of micronized versions of titanium dioxide and zinc oxide. With particle sizes of less than 0.2 micrometers, these formulations are nearly imperceptible on all but the darkest skin tones, making them much more appealing.

Traditionally, physical agents used to prevent sunburn were called ‘sunblocks’ while chemical agents were ‘sunscreens’. The terminology is misleading because it suggests that the former merely scatter or reflect UV radiation. In fact, the physical (also called inorganic or insoluble) agents, titanium dioxide and zinc oxide, also act as semiconductors that absorb UV radiation and release it as heat. The use of the term ‘chemical-free’ for sunscreens containing only physical, not chemical, sunscreen agents is also confusing for consumers, since all active and inactive ingredients have been obtained and/or combined through some chemical process. The FDA-approved maximum concentration of these agents in sunscreen is listed in Table 20.2.

Table 20.2 Sunscreen active ingredients: physical

Active ingredient Maximum concentration (%)
Titanium dioxide 25
Zinc oxide 25

RATING EFFICACY

With appropriate ultraviolet protection, exposed individuals do not suffer significant cutaneous DNA damage, sunburn cell formation, or immunosuppression. Clinically, sunscreen use significantly reduces the occurrence of actinic keratoses, nonmelanoma skin cancer, and skin aging. Daily application of sunscreen decreases the number of acquired nevi in children. Although intermittently raised as an issue, sunscreen use has not been proven to cause significant secondary vitamin D deficiency and will be addressed later in the chapter.

The ultraviolet spectra relevant to cutaneous damage are UVB (290–320 nm) and UVA (320–400 nm). Ultraviolet A radiation is further classified as UVA II (320–340 nm) and UVA I (340–400 nm). Clinically, excessive acute UVB exposure results in the classic sunburn. Multiple acute UVB assaults early in life have been linked with basal cell carcinoma and melanoma. The development of actinic keratoses and squamous cell carcinoma are more closely causally linked to chronic UVB exposure. Absorption of UVB by DNA mutates the p53 tumor suppressor gene and initiates the formation of pyrimidine dimers, an elevated level of which are mutagenic and linked to cutaneous carcinogenesis.

UVA may be a more silent threat than the erythemogenic UVB. A significant amount of UVB is screened by the stratospheric ozone layer, so terrestrial surface sunlight contains 20 times more UVA than UVB. Unlike UVB, UVA can penetrate window glass, and is relatively unchanged by time of day, season, and altitude. UVA can produce tanning and dyspigmentation without preceding erythema. The longer wavelengths penetrate deep into the dermis causing many of the histologic and clinical changes associated with photoaging. UVA I causes immunosuppression through the depletion of Langerhans’ cells and reduced activity of antigen-presenting cells. UVA also indirectly damages DNA through the formation of oxygen free radicals, mechanisms thought to contribute to carcinogenesis. Indeed, studies in animal models suggest that UVA may play a significant role in the development of malignant melanoma.

Sunscreen ingredients differ in their absorption spectrum, as shown in Table 20.3. Ideally a sunscreen should provide protection against the full spectrum of ultraviolet radiation. Until now most of the focus of the FDA’s attention has been on reducing exposure to UVB light. The sun protection factor (SPF), which measures UVB protection, was the only internationally standardized measure of a sunscreen’s ability to filter UV radiation. It is the ratio of the UV energy required to produce a minimal erythema dose (MED) on sunscreen-protected skin to the UV energy required to produce a MED on unprotected skin (Box 20.1). The MED is the quantity of energy required to produce the first perceptible redness reaction of the skin with clearly defined borders. Energy is delivered utilizing a filtered light source simulating the solar emission spectrum, with 94% of its output between 290 and 400 nm. (This mimics sunlight at sea level at a zenith angle of 10°.) For any given product, measurement must be done on between 20 and 25 test subjects of Fitzpatrick skin types I, II, and III. Test material is applied to an area of at least 50 cm2 at a thickness of 2 mg/cm2.

Table 20.3 Absorbance range of selected sunscreen active ingredients

Sunscreen Absorbance range (nm)
Homosalate 300–310
Octyl salicylate 300–310
Aminobenzoic acid (PABA) 260–313
Padimate O 290–315
Methyl anthralinate 290–320
Phenylbenzimidazole sulfonic acid 290–320
Trolamine salicylate 260–320
Cinoxate 270–328
Octyl methoxycinnamate 270–328
Oxybenzone 270–350
Sulisobenzone 270–360
Dioxybenzone 260–380
Zinc oxide 250–380
Avobenzone 310–400
Ecamsule 290–400
Titanium dioxide 250–400

The SPF of a given OTC topical sunscreen is determined by testing of that product as above. In accordance with FDA regulations, multiple sun protective active ingredients can be combined as long as each contributes a minimum SPF of at least 2 to the finished product. This requirement is meant to avoid the addition of unnecessary ingredients. FDA will revise some of the existing SPF testing procedures to decrease the health risk to persons enrolled in the SPF test and further enhance accuracy of SPF values.

It is important to note that certain ingredients are incompatible and, if combined, will reduce the final SPF of a product. For example, avobenzone is unstable when combined with cinnamates such as cinoxate, but is both stable and effective when combined with octocrylene. Conversely, combining other active ingredients can increase the level of sun protection by improving photostability. Both avobenzone and oxybenzone have been reported to undergo degradation after UV irradiance. The physical sunscreen ingredients, titanium dioxide and zinc oxide, have been shown to improve the survival of chemical sunscreens in vitro. The FDA is recognizing new combinations of active ingredients of avobenzone with either zinc oxide or ensulizole.

Furthermore, the FDA is amending its existing 1999 monograph and changing the highest SPF values from 30 + up to 50 +. When data that support accurate testing of sunscreens higher than 50 are reproduced, revising the upper limit of SPF will again be permitted in labeling.

Additionally, the proposed rule renames ‘SPF’ from ‘sun protection factor’ to ‘sunburn protection factor’, and sunscreen product labels would be required to include ‘UVB’ alongside ‘SPF’ so that consumers know that SPF values reflect UVB sunburn protection. Despite the proposed changes and improvements in SPF guidelines, there are still significant limitations. For example, thickness of application used to measure SPF may be unrealistic under ordinary, nontest conditions, thereby giving the consumer false confidence while significantly lowering the functional SPF. Moreover, people who use high SPF value sunscreens (who might otherwise have limited their ultraviolet exposure due to a fear of sunburn) may remain outdoors longer and accumulate more ultraviolet damage.

Regulations concerning UVA were delayed until recently since reliable testing methodologies were not available. However, the new proposed regulations address manufacturing, testing, and labeling of UVA sunscreens. Sunscreen manufacturers will now have to post the degree of protection afforded by a particular product against UVA rays. The scale of one to four stars corresponding to low, medium, high or very high UVA protection is to be prominently displayed on OTC sunscreen products near the SPF rating (Figs 20.1 and 20.2). Because consumers are familiar with SPF numbers, the FDA believes there may be confusion if UVB and UVA protection levels were both identified by numbers. Since star rating has been used in a variety of industries (e.g. hotels and restaurants), the FDA expects consumers will learn how to use this information to select the appropriate sunscreen, as they have done with SPF values. Furthermore, the product will bear a ‘no UVA protection’ marking on the front label if the sunscreen does not provide even a low level of protection.

Table 20.4 outlines the in vivo and in vitro options available. Immediate pigment darkening (IPD) measures the transient brown color that appears and fades within minutes of UVA exposure in vivo in darker skin types. The persistent pigment darkening (PPD) technique has an easier to assess endpoint: pigment due to melanin oxidation that can be measured 24 hours after exposure in vivo. The protection factor in the UVA (PFA) method is also read in vivo at 24 hours and assesses either erythema or tanning. In vitro, the critical wavelength (λc) below which 90% of a sunscreen’s UV absorbance occurs is between 290 and 400 nm. That means that a product with a λc of 340 nm would filter UVB and UVA II, but not UVA I.

Table 20.4 Methods of testing UVA protection

Test Skin types used Time of reading
In vivo
Immediate pigment darkening (IPD) III–V Immediate
Persistent pigment darkening (PPD) II–IV 24 hours
Protection factor in the UVA (PFA or APF) I–IV 24 hours
In vitro
Critical wavelength (λc)

The FDA has conducted thorough analyses of data and information related to UVA tests and is proposing a standard testing protocol. Ratings would be derived from two tests to give an accurate and reproducible assessment of UVA protection. The in vivo clinical test assesses how well a sunscreen reduces darkening of the skin, similar to SPF testing that measures how well the sunscreen reduces burning. The nonclinical test is an in vitro test (performed on a quartz plate) and rates the product’s ability to reduce the amount of UVA radiation passing through the sunscreen. The results will be combined to generate a single UVA rating, which will be the lower of the two values. For example, if one test indicates a medium level of UVA protection while the other denotes a high level, the sunscreen is labeled as medium level of UVA protection.

With the recent FDA proposed regulations, using sunscreens liberally and reapplying frequently is advised since the efficacy of a sunscreen is affected by environmental factors including humidity and activity. For instance, sunscreens can be physically rubbed off by toweling or washed off when swimming or with heavy sweating. Additionally, some active ingredients in sunscreens start to break down over time and can be accelerated by sun exposure.

Since swimming and sweat-inducing sports are most commonly warm weather, daytime, outdoor activities, the ability of a sunscreen to maintain its filtering abilities under wet conditions is critical. ‘Water resistance’ is defined as maintenance of the label SPF value after 40 minutes of water immersion in a fresh water pool, whirlpool, or jacuzzi, consisting of two 20-minute periods of moderate activity separated by a 20-minute rest period and concluded by air drying without toweling. To be ‘very water resistant’, the sunscreen must maintain its SPF over a test cycle including 80 minutes of moderate activity in water. Manufacturers will be required to amend claims that their products are truly ‘waterproof’ or ‘sweatproof’ because the FDA does not believe these are accurate statements.

In addition to the new rating system, the FDA wants sunscreen labels to advise consumers that using a sunscreen is just one way they can protect themselves against the sun and that a comprehensive sun protection regimen is important. A warning statement has been proposed to all sunscreen product manufacturers. The warning will mention that: ‘UV exposure from the sun increases the risk of skin cancer, premature skin aging, and other skin damage. It is important to decrease UV exposure by limiting time in the sun, wearing protective clothing, and using a sunscreen.’

PHOTOSTABILITY

Photochemical stability is a vital characteristic of an effective UV filter. It refers to the ability of a molecule to remain intact and not undergo degradation with irradiation. Photoinstability reduces the photoprotective efficacy and can promote phototoxic or photoallergic contact dermatitis. Additionally, it can result in formation of free radicals causing photo-oxidative stress that can damage DNA and denature proteins. The ideal sunscreen should be such that no photochemical instability of its components occurs within the formulation or on the skin. However, achieving a photostable formulation is a challenge mainly due to inherent instabilities of certain organic substances used in sunscreens. This issue has been raised specifically with avobenzone but also noted with octyl methoxycinnamate and octyl dimethyl PABA. Photostability can also be affected by the solvent or the vehicle used and many products now contain ingredients that stabilize the effect of others as well as offering a protective additive.

Such examples include the following.

DOSAGE AND USAGE

The current FDA standard for sunscreen application is 2 mg/cm2 and yet studies suggest that actual usage is only 25–50% of the amount used to rate sunscreen SPF. The main problem with sunscreen effectiveness is the nonlinear relationship between the SPF rating and the amount applied to the skin (Fig. 20.3). Sunscreen application has been shown to be as little as 0.5 mg/cm2 which would translate to an SPF of 8 or 15 when applying an SPF product of 30. To cover the average 1.73 m2 adult, a total of 35 mL of sunscreen is required.

The question then centers on why there is such a large discrepancy between how much sunscreen is needed and the amount actually used. There are numerous possibilities, starting with the consumer. Some sunscreen users feel uncomfortable at the recommended doses. Products may feel thick and occlusive, and at the appropriate dose can look opaque. There is a lack of education and specific instructions. Directions on sunscreen labels can be vague, with language such as ‘apply liberally to all exposed areas prior to sun exposure’. The public may not understand how much is actually required, or may not have a good grasp on what 35 mL translates to clinically. This should be countered by relating the amount of product required with a common measurement that individuals can understand. Schneider (Fig. 20.4) suggests the ‘teaspoon rule’ based on the rule of nines used for calculating burn areas. With the teaspoon rule, an adult should apply approximately one-half teaspoon to each arm and to the face and neck. Six milliliters (just a little more than a teaspoon) should be applied to each leg, the chest, and to the back. This would amount to 33 mL being used. Another measurement most adults understand is the shot glass used to mix drinks. A shot glass is 30 mL and would approximate the requirement. Another method employed by some physicians is to recommend that patients apply twice or to put on two layers. This should increase the amount applied and may help to reduce the number of ‘missed’ or ‘skipped’ areas. One of the biggest obstacles to proper dosing, however, is the desire by many Americans and Europeans to have tanned skin.

Besides the amount of sunscreen applied, there are a number of factors that also influence the protection equation and the best dosing regimen. These include resistance to water immersion and sand abrasion, reapplication, and the way products are applied. A mathematical study examined the relative importance of three sunscreen related factors: the amount of sunscreen applied, how the sunscreen was spread, and the UVA absorbing property of sunscreen. Diffey calculated that approximately 75% of the variance in UVA photoprotection achieved clinically depends upon how much product is applied. How well the product is applied and how well it absorbs UVA contributed almost equally to the remaining 25% of the variance.

Important in any discussion of sunscreen dosing is the proper timing for reapplication as discussed earlier. Substantivity of a sunscreen is an indication of how well it maintains its degree of protection. Factors influencing the need for reapplication include water activities, perspiration and rubbing of clothing or towels, and sand abrasion. It is generally recommended that the public reapply sunscreen every 2 hours and after swimming, towel drying, or sweating. However, this may not be sufficient. Diffey advises that sunscreen be applied 15–30 minutes prior to sun exposure and reapplication of the product 15–30 minutes after sun exposure begins.

ADVERSE EVENTS

Adverse events can be divided into direct reactions (Box 20.2) such as contact allergic reactions, and indirect sequelae such as increased UV exposure. The latter are more difficult to quantify and, to date, are less well defined.

• Direct adverse events

Despite improvements in the formulations, there are still a number of reactions that occur, including idiosyncratic reactions to any of the components. With the higher SPF products, several active ingredients may be used in one formulation and at higher concentrations, increasing the potential for contact reactions. Companies, vying for consumers, are adding antioxidants, fragrances, preservatives, emulsifiers, and stabilizers, which can also cause adverse reactions.

Contact irritant reactions are by far the most common adverse event. Over 90% of cosmetic side effects are irritant reactions and half of these are subjective only. Also, some products may aggravate pre-existing conditions such as acne rosacea, atopic dermatitis, and seborrheic dermatitis. A true contact allergic reaction is typically seen 48 hours after exposure and, like other delayed hypersensitivity reactions, presents with a spongiotic dermatitis. The offending agent acts as a hapten to bind with endogenous proteins and activates T lymphocytes. An immediate contact urticaria can be caused by sunscreens, with a wheal and flare reaction developing within 30–60 minutes after exposure. In one study using sunscreen or its vehicle, 19% (114 of 603 subjects) of the study population had adverse reactions. True allergic sensitization was seen in 6, while 45 patients developed aggravation of their atopic dermatitis, 39 had a contact irritation, and 22 had nonspecific cosmetic intolerance.

Phototoxic and photoallergic reactions are possible with current sun protectant products. A phototoxic reaction can occur when UV radiation is absorbed and can then be transferred to epidermal cells causing an exaggerated sunburn, or can promote photoexcitation of the agent. These reactive singlets or triplets can damage various portions of the cell including the cell membrane, DNA, and lysosomes. Padimate A, a PABA ester, was found to be quite phototoxic and was withdrawn from the market. A photoallergic reaction is a contact allergic reaction that requires UV radiation to transform the chemical into a sensitizer. Photoallergy most often involves the UVA portion of the UV spectrum. The use of effective UVA blockers should help to minimize UVA absorption and prevent photoallergic responses.

• Indirect adverse events

The debate on vitamin D and sunscreens continues. Anywhere from 9 to 40% of Americans are deficient in vitamin D. The prevalence of vitamin D deficiency is especially high in the elderly due to a combination of decreased dietary intake, diminished absorption, and limited exposure to sunlight. Current research suggests that older adults should take at least 800 IU with at least 1.2 g of elemental calcium in the diet or as a supplement in order to prevent fractures. Most multivitamins contain 400 IU/day. The intake at which the dose of vitamin D becomes toxic is not clear, but is somewhere above 2000 IU per day.

Although vitamin D can be added to the diet in supplements, milk, cereal and other foods, 90% of requisite vitamin D is formed within the skin through the action of the sun. A number of studies point to a protective role of vitamin D in the pathogenesis of various malignancies, including colon, prostate, and breast cancer. Thus two separate but related adverse events are at least theoretically possible with the regular use of sunscreen: deficiency in vitamin D, and an increased risk of some internal cancers, especially in those individuals who might already be at risk for vitamin D deficiency. This can be balanced with adequate dietary intake of vitamin D, supplemental use of vitamin D, or exposure to small amounts of sunlight. A study performed in Boston, Massachusetts, demonstrated that exposure of the body in a bathing suit to one minimal erythema dose of sunlight is equivalent to injecting about 10 000 IU of vitamin D. However, more limited exposure, such as the hands, arms, and face, will require exposure two to three times a week at one-third to one-half a minimal erythema dose.

Despite the theoretical risk of producing vitamin D deficiency, there is no conclusive evidence to support these risks with regular use of OTC sunscreens. Dr Gilchrest and her colleagues from Boston University reviewed this topic and have noticed very small amounts of sun exposure provide all the vitamin D the body can manufacture and that some UV rays still reaches the skin even when wearing sunscreens. This may be plenty, at least for fair-skinned individuals. Greater exposure only increases DNA damage while not adding to vitamin D stores. It is our belief that sunscreen use should not be reduced.

There has been additional concern that the use of sunscreen may actually increase the risk for developing melanoma, but an analysis of 14 studies published to date could not confirm an increased risk for melanoma developing after sunscreen use. There is concern that fair skinned individuals will increase their exposure to the sun with a false sense of security when using sunscreens. This is especially a problem if the sunscreen used has a high SPF rating but lacks adequate UVA coverage. Statistically US adolescents still have one or more summer sunburns and many adolescents reported having used sunscreen with a SPF of 15 or higher before receiving their most serious summer sunburn. These types of studies fail to demonstrate whether the teenagers would have sunburned without the use of a sunscreen, and would they indeed decrease risky sun behaviors if they did not have the aid of a sunscreen agent.

Thus the debate about indirect side effects is sure to continue for some time.

• Ingredient-specific adverse events

NEW RESEARCH

Clearly there is a need for sunscreens that are efficacious at lower application densities to mimic what is frequently applied by the public in ‘normal use’ perhaps to 0.025–0.5 mg/cm2. Another area of improvement is in base or vehicle enhancement so that a better flow property would lessen uneven applications and allow for longer duration while still remaining cosmetically appealing. Sunscreens that are able to impart a ‘tanned’ appearance may have a role, especially for adolescents, such that it would encourage their usage.

The most promising research, however, lies in the use of additives that have a synergistic property with the sunscreen. Most notably, the addition of antioxidants could potentially limit the damage from UV photons and help to repair some of the genetic damage induced by UV photons that have penetrated the skin. Vitamin C has been demonstrated to modestly protect against UVB photodamage and UVA-induced phototoxic responses. When combined with vitamin E there may be an even greater protection against cellular insult. Beta-carotene has been reported to be of value in the treatment of erythropoietic protoporphyria and may be able to inhibit UV-promoted carcinogenesis. Selenium compounds, when topically applied in concentrations of less than 0.05%, reduce UV skin damage measured as less inflammation, less pigmentation, and retardation of skin cancer. Chelates such as ortho-phenanthroline, edetic acid, and dipyridylamine bind metals such as iron, thus limiting their interactions with other materials and protecting against cellular damage from free radical oxygen. Topical chelate application prior to UV exposure is reported to reduce or delay visible skin wrinkling caused by UV exposure along with tumor formation.

It is important to remember that, to date, innovations in sunscreens have had little direct effect on sun-induced tumor incidence rates such as basal cell carcinoma and melanoma. This may be due to the additional use of tanning beds and other sun-seeking behaviors, and current attitudes towards sun exposure and the continued appeal of ‘tanned’ skin. There are animal models and human studies which indicate that the use of high SPF sunscreen reduces the number of new actinic keratoses and leads to a reduction in recurrent squamous cell carcinomas.

When used appropriately and with other measures to help retard UV exposure such as behavior changes and the use of clothing, sunscreens can be a very important tool.

FURTHER READING

Albert MR, Ostheimer KG. The evolution of current medical and popular attitudes toward ultraviolet light exposure: Part 3. Journal of the American Academy of Dermatology. 2003;49:1096–1106.

Al Mahroos MA, Yaar M, Phillips TJ, et al. Effect of sunscreen application on UV-induced thymine dimers. Archives of Dermatology. 2002;138:1480–1485.

Bastuji-Garin S, Diepgen T. Cutaneous malignant melanoma, sun exposure, and sunscreen use: epidemiological evidence. British Journal of Dermatology. 2002;146(Suppl 61):24–30.

Benech-Kieffer F, Meuling WJ, Leclerc C, et al. Percutaneous absorption of Mexoryl SX in human volunteers: comparison with in vitro data. Skin Pharmacology and Applied Skin Physiology. 2003;16:343–355.

Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. Journal of the American Medical Association. 2005;293:2257–2264.

Bissonnette R, Allas S, Moyal D, et al. Comparison of UVA protection afforded by high sun protection factor sunscreens. Journal of the American Academy of Dermatology. 2000;43:1036–1038.

Chatelain E, Gabard B. Photostabilization of butyl methoxydibenzoylmethane (Avobenzone) and ethylhexyl methoxycinnamate by bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a new UV broadband filter. Photochemistry and Photobiology. 2001;74:401–406.

Damiani E, Greci L, Parsons R, et al. Nitroxide radicals protect DNA from damage when illuminated in-vitro in the presence of dibenzoylmethane and a common ingredient. Free Radical Biology and Medicine. 1999;26:809–816.

Darlington S, Williams G, Neale R, et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Archives of Dermatology. 2003;139:451–455.

Davies MJ. Reactive species formed on proteins exposed to singlet oxygen. Photochemical and Photobiological Sciences. 2004;3:17–25.

Deflandre A, Lang G. Photostability assessment of sunscreens. Benzylidene camphor and dibenzoylmethane derivatives. International Journal of Cosmetic Science. 1988;10:53–62.

DeLeo VA, Suarez SM, Maso MJ. Photoallergic contact dermatitis. Archives of Dermatology. 1992;128:1513–1518.

Diffey BL. Sunscreens, suntans, and skin cancer. People do not apply enough sunscreen for protection. British Journal of Dermatology. 1996;313:942.

Diffey BL. Sunscreen isn’t enough. Journal of Photochemistry and Photobiology B. 2001;64:105–108.

Diffey BL. Sunscreens and UVA protection: a major issue of minor importance. Photochemistry and Photobiology. 2001;74:61–63.

Diffey BL. When should sunscreen be reapplied? Journal of the American Academy of Dermatology. 2001;45:882–885.

Foley P, Nixon R, Marks R, Frowen K, Thompson S. The frequency of reactions to sunscreens: results of a longitudinal population-based study on the regular use of sunscreens in Australia. British Journal of Dermatology. 1993;128:512–518.

Fourtanier A, Labat-Robert J, Kern P, et al. In vivo evaluation of photoprotection against chronic ultraviolet-A irradiation by a new sunscreen Mexoryl SX. Photochemistry and Photobiology. 1992;55:549–560.

Farrerons J, Barnadas M, Rodríguez J, et al. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers. British Journal of Dermatology. 1998;139:422–427.

Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354:723–729.

Hawk JL. Cutaneous photoprotection. Archives of Dermatology. 2003;139:527–530.

Kielbassa C, Epe B. DNA damage by UV and visible light and its wavelength dependence. Methods in Enzymology. 2000;319:436–445.

LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult Vitamin D deficiency in postmenopausal US women with acute hip fracture. Journal of the American Medical Association. 1999;281:1505–1511.

Lim HW, Naylor M, Honigsmann H, et al. American Academy of Dermatology Consensus Conference on UVA protection of sunscreens: summary and recommendations. Journal of the American Academy of Dermatology. 2001;44:505–508.

Marks R, Foley PA, Jolley D, et al. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Archives of Dermatology. 1995;131:415–421.

Marrot L, Belaidi JP, Chaubo C, et al. An in vitro strategy to evaluate the phototoxicity of solar UV at the molecular and cellular level: application to photoprotection assessment. European Journal of Dermatology. 1998;8:403–412.

Meves A, Repacholi MH, Rehfuess EA. Promoting safe and effective sun protection strategies. Journal of the American Academy of Dermatology. 2003;49:1203–1204.

Mitchnick MA, Fairhurst D, Pinnell SR. Microfine zinc oxide (Z-cote) as a photostable UVA/UVB sunblock agent. Journal of the American Academy of Dermatology. 1999;40:85–90.

Moloney F, Collins S, Murphy G. Sunscreens safety, efficacy and appropriate use. American Journal of Clinical Dermatology. 2002;3:185–191.

Naylor M, Boyd A, Smith D, Cameron GS, Hubbard D, Neldner K. High sun protection factor sunscreens in the suppression of actinic neoplasia. Archives of Dermatology. 1995;131:170–175.

Osborne J, Hutchinson P. Vitamin D and systemic cancer: is this relevant to malignant melanoma? British Journal of Dermatology. 2002;147:197–213.

Ravanat JL, Martinez GR, Medeiros MH, et al. Mechanistic aspects of the oxidation of DNA constituents mediated by singlet molecular oxygen. Archives of Biochemistry and Biophysics. 2004;423:23–30.

Schneider J. The teaspoon rule of applying sunscreen. Archives of Dermatology. 2002;138:838–839.

Seite S, Moyal D, Richard S, et al. Mexoryl SX: a broad absorption UVA filter protects human skin from the effects of repeated suberythemal doses of UVA. Journal of Photochemistry and Photobiology B. 1998;44:69-76.

Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: six years’ experience with xeroderma pigmentosum. Journal of the American Academy of Dermatology. 1997;37:942–947.

Szczurko C, Dompmartin A, Michel M, Moreau A, Leroy D. Photocontact allergy to oxybenzone: ten years of experience. Photodermatology, Photoimmunology and Photomedicine. 1994;10:144–147.

Tarras-Wahlberg N, Stenhagen G, Larko O, et al. Changes in ultraviolet absorption of sunscreens after ultraviolet irradiation. Journal of Investigative Dermatology. 1999;113:547–553.

US Food and Drug Administration. Center for Food Safety and Applied Nutrition, Office of Cosmetics and Colors Fact Sheet: Sunscreens, tanning products, and sun safety. Online. Available: http://www.cfsan.fda.gov/∼dms/cos-sun.html, 2003.

US Food and Drug Administration, HHS. Sunscreen drug products for over-the-counter human use; final monograph. Federal Register. 64(98), 1999.

Wolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? Journal of the American Academy of Dermatology. 2006;54:301–317.

Internet resources for FDA updates on sunscreens: http://www.fda.gov/consumer/updates/sunscreen082307.html